Cosmo Pharmaceuticals Equity 2024

Cosmo Pharmaceuticals Aktienanalyse

What does Cosmo Pharmaceuticals do?

Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cosmo Pharmaceuticals's Equity

Cosmo Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cosmo Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cosmo Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cosmo Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cosmo Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cosmo Pharmaceuticals stock

What is the equity of Cosmo Pharmaceuticals this year?

Cosmo Pharmaceuticals has equity of 0 EUR this year.

What was the equity of Cosmo Pharmaceuticals compared to the previous year?

The equity of Cosmo Pharmaceuticals has increased/decreased by -100% decreased compared to the previous year.

What impact does a high equity have on investors of Cosmo Pharmaceuticals?

A high equity is advantageous for investors of Cosmo Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cosmo Pharmaceuticals?

A low equity can be a risk for investors of Cosmo Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cosmo Pharmaceuticals affect the company?

An increase in equity of Cosmo Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cosmo Pharmaceuticals affect the company?

A reduction in equity of Cosmo Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cosmo Pharmaceuticals?

Some factors that can affect the equity of Cosmo Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cosmo Pharmaceuticals so important for investors?

The equity of Cosmo Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cosmo Pharmaceuticals take to change the equity?

To change equity, Cosmo Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cosmo Pharmaceuticals pay?

Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.

What is the dividend yield of Cosmo Pharmaceuticals?

The current dividend yield of Cosmo Pharmaceuticals is 1.29 %.

When does Cosmo Pharmaceuticals pay dividends?

Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, June, June, August.

How secure is the dividend of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals paid dividends every year for the past 8 years.

What is the dividend of Cosmo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.29 %.

In which sector is Cosmo Pharmaceuticals located?

Cosmo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cosmo Pharmaceuticals from 7/12/2024 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did Cosmo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Cosmo Pharmaceuticals in the year 2023?

In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.

In which currency does Cosmo Pharmaceuticals pay out the dividend?

The dividends of Cosmo Pharmaceuticals are distributed in EUR.